Metraipolis › archive › dc_4bc50fc5629c

Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China — Europe PMC PMID:42466000

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42466000
DOI
10.3389/fphar.2026.1864488
License (as archived)
solo-consultazione
Archived
2026-10-18T12:09:13.384Z
SHA-256 of the archived text
77ab44236f8f47633b023c6ebedcb74fb5171673852b422f61d8ca20f36edf9a
Stable URL of this page
https://metraipolis.com/documento/dc_4bc50fc5629c

How to cite

Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China — Europe PMC PMID:42466000 — Europe PMC (en), https://europepmc.org/article/MED/42466000 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4bc50fc5629c (Metraipolis archive dc_4bc50fc5629c, sha256 77ab44236f8f47633b023c6ebedcb74fb5171673852b422f61d8ca20f36edf9a)
BibTeX
@misc{dc4bc50fc5629c,
  title = {Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China — Europe PMC PMID:42466000},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42466000},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4bc50fc5629c; sha256 77ab44236f8f47633b023c6ebedcb74fb5171673852b422f61d8ca20f36edf9a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42466000. Agents can read the archived copy with the MCP tool read_document.